Bariatric Surgery Associated with a Lower Rate of Mortality Due to Infarction and Stroke

Prior bariatric surgery in a patient with morbid obesity is associated with a significant effect on survival after infarction or stroke.

TAVI: la estrategia minimalista es favorable en el EPOC severo

While these are observational data, the significant metabolic improvement experienced after the surgery can explain perfectly such findings.

This large nationwide registry of bariatric surgery found a 40% decrease in the risk of death, infarction, or stroke for these patients compared with patients who did not undergo such surgery. This benefit is still observed after individuals are matched by body mass index (BMI). There already are many small studies showing similar data for obese patients who undergo bariatric surgery. Bariatric surgery has also proven to be an effective and durable treatment for type 2 diabetes, although the mechanisms for such effect are not entirely understood.


Read also: Nonobstructive Coronary Lesions and Ventricular Dysfunction


The US bariatric surgery database sponsored by the Agency for Healthcare Research and Quality assessed 995,577 patients hospitalized for acute myocardial infarction and 917,610 for stroke over an 8-year period. Of these, 2218 patients with infarction and 2,168 with stroke had undergone prior bariatric surgery. Those patients were compared with a control group of morbidly obese patients with the same risk characteristics using propensity score matching.

Death due to infarction was 1.85% in patients with prior bariatric surgery compared with 3.03% in morbidly obese patients (p = 0.004). Similar results were observed with stroke: 1.43% vs. 2.74% (p = 0.001).

An analysis using BMI to match patients showed nearly identical results.


Read also: New Percutaneous Devices to Prevent Embolism in Atrial Fibrillation.


Bariatric surgery should have never been seen as a cosmetic procedure, but rather a tool to treat metabolic disease.

Original Title: Bariatric Surgery is Associated with a Lower Rate of Death after Myocardial Infarction and Stroke: a Nationwide Study.

Reference: Aminian A et al. Diabetes Obes Metab. 2019 May 3. [Epub ahead of print].

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

TAVR and Anticoagulation: What Should We Do?

Transcatheter aortic valve replacement (TAVR) has consolidated as a valid strategy for certain groups of patients. However, approximately one third of those who require...

Direct Oral Anticoagulants for Ventricular Thrombus After STEMI

While the incidence of intracavitary thrombi after acute myocardial infarction (AMI) has decreased thanks to optimized primary angioplasty times, some studies report rates of...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...